Effects of percutaneous estradiol–oral progesterone versus oral conjugated equine estrogens–medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women
In a prospective, randomized clinical study 77 women were assigned randomly to receive sequential hormone therapy with either conventional oral conjugated equine estrogens (0.625 mg) with the addition on 14 of the 28 days of oral medroxyprogesterone acetate (5 mg) or natural E2 gel (1.5 mg) with ora...
Gespeichert in:
| Veröffentlicht in: | Fertility and sterility 2011-03, Vol.95 (3), p.1188-1191 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1191 |
|---|---|
| container_issue | 3 |
| container_start_page | 1188 |
| container_title | Fertility and sterility |
| container_volume | 95 |
| creator | Murkes, Daniel, M.D Conner, Peter, M.D., Ph.D Leifland, Karin, M.D., Ph.D Tani, Edneia, M.D., Ph.D Beliard, Aude, M.D., Ph.D Lundström, Eva, M.D., Ph.D Söderqvist, Gunnar, M.D., Ph.D |
| description | In a prospective, randomized clinical study 77 women were assigned randomly to receive sequential hormone therapy with either conventional oral conjugated equine estrogens (0.625 mg) with the addition on 14 of the 28 days of oral medroxyprogesterone acetate (5 mg) or natural E2 gel (1.5 mg) with oral micronized P (200 mg) on 14 of the 28 days of each cycle. Because oral conjugated equine estrogens–medroxyprogesterone acetate induced a highly significant increase in breast cell proliferation in contrast to percutaneous E2 –oral P with a difference between therapies approaching significance, the former therapy has a marked impact on the breast whereas natural percutaneous E2 –oral micronized P has not. |
| doi_str_mv | 10.1016/j.fertnstert.2010.09.062 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_547886</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0015028210026750</els_id><sourcerecordid>853471099</sourcerecordid><originalsourceid>FETCH-LOGICAL-c664t-6d62aa01054d6c183c2282d3fea9ce348b3480148af152779383e52a57fd3f063</originalsourceid><addsrcrecordid>eNqNk81u1DAQxyMEoqXwCuAL4pTFdmLHuSDRqnxIlTiUni3HmWy9zdpbO2nZG-_A4_A2PAmTzbYVSEhI-bDGv79nPP47ywijC0aZfLtadBAHnwb8LjjFMK0XVPJH2SETQuZCiuJxdkgpEznlih9kz1JaUUolq_jT7IAzKquKV4fZz9OuAzskEjqygWjHwXgIYyKQhmhaF_pf33-EaHqyiWEJU8bggdxATAjtJmzwq3FpBmgJXI8OZyctwj6hdg1tDN-2f6iNhQF5EjxpIpg0EAv9LkPvcGNmcDhjfEsa2-d8ig_gPMHnEkw_XG7JbViDf5496Uyf4MX-f5RdfDj9evIpP_vy8fPJ-7PcSlkOuWwlNwabJMpWWqYKy7ElbdGBqS0UpWrwpaxUpmOCV1VdqAIEN6LqEKKyOMryed10C5ux0Zvo1iZudTBO70NXOAItykqpia__yeNe2gfRnZBxTmlJlUJtMWt7B0vQITZO3_CddDce-6U2VjegOZdKM1EIQVH1Zlbh8tcj9lmvXZp6Oh-mVqIoK0brGkk1kzaGlCJ099Uxqidv6ZV-8JaevKVprdFbKH25TzI2eKr3wjszIfB6D5hkTd9F461LD1xRM6l2_Xw1c50J2iwjMhfnmEmgX3lVVgUSxzMBeKw3DqJO1oG30LqIbtVtcP9T77u_FrG98w4ru4ItpFUYo0fbaKYT11SfT7dluiyMUi4r7Opv7mIZHw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>853471099</pqid></control><display><type>article</type><title>Effects of percutaneous estradiol–oral progesterone versus oral conjugated equine estrogens–medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women</title><source>MEDLINE</source><source>SWEPUB Freely available online</source><source>Access via ScienceDirect (Elsevier)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Murkes, Daniel, M.D ; Conner, Peter, M.D., Ph.D ; Leifland, Karin, M.D., Ph.D ; Tani, Edneia, M.D., Ph.D ; Beliard, Aude, M.D., Ph.D ; Lundström, Eva, M.D., Ph.D ; Söderqvist, Gunnar, M.D., Ph.D</creator><creatorcontrib>Murkes, Daniel, M.D ; Conner, Peter, M.D., Ph.D ; Leifland, Karin, M.D., Ph.D ; Tani, Edneia, M.D., Ph.D ; Beliard, Aude, M.D., Ph.D ; Lundström, Eva, M.D., Ph.D ; Söderqvist, Gunnar, M.D., Ph.D</creatorcontrib><description>In a prospective, randomized clinical study 77 women were assigned randomly to receive sequential hormone therapy with either conventional oral conjugated equine estrogens (0.625 mg) with the addition on 14 of the 28 days of oral medroxyprogesterone acetate (5 mg) or natural E2 gel (1.5 mg) with oral micronized P (200 mg) on 14 of the 28 days of each cycle. Because oral conjugated equine estrogens–medroxyprogesterone acetate induced a highly significant increase in breast cell proliferation in contrast to percutaneous E2 –oral P with a difference between therapies approaching significance, the former therapy has a marked impact on the breast whereas natural percutaneous E2 –oral micronized P has not.</description><identifier>ISSN: 0015-0282</identifier><identifier>ISSN: 1556-5653</identifier><identifier>EISSN: 1556-5653</identifier><identifier>DOI: 10.1016/j.fertnstert.2010.09.062</identifier><identifier>PMID: 21067727</identifier><identifier>CODEN: FESTAS</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>acetates ; Administration, Oral ; bcl-2 protein ; Biological and medical sciences ; Biopsy ; breast ; Breast - cytology ; Breast - drug effects ; Breast - metabolism ; Breast Neoplasms - epidemiology ; Breast Neoplasms - prevention & control ; Cell Division - drug effects ; cell proliferation ; Contraceptive Agents, Female - administration & dosage ; Contraceptive Agents, Female - adverse effects ; estrogen ; Estrogen Replacement Therapy - adverse effects ; Estrogen Replacement Therapy - methods ; estrogens ; Estrogens - administration & dosage ; Estrogens - adverse effects ; Estrogens, Conjugated (USP) - administration & dosage ; Estrogens, Conjugated (USP) - adverse effects ; Female ; gels ; Gynecology. Andrology. Obstetrics ; hormone replacement therapy ; horses ; Human health sciences ; Humans ; Internal Medicine ; Medical sciences ; Medicin och hälsovetenskap ; medroxyprogesterone ; Medroxyprogesterone Acetate - administration & dosage ; Medroxyprogesterone Acetate - adverse effects ; micronized progesterone ; Médecine de la reproduction (Gynécologie, andrologie, obstétrique) ; normal breast tissue ; Obstetrics and Gynecology ; Percutaneous estradiol ; progesterone ; proliferation ; Prospective Studies ; Proto-Oncogene Proteins c-bcl-2 - metabolism ; randomized clinical trials ; Reproductive medicine (gynecology, andrology, obstetrics) ; Risk Factors ; Sciences de la santé humaine ; women</subject><ispartof>Fertility and sterility, 2011-03, Vol.95 (3), p.1188-1191</ispartof><rights>American Society for Reproductive Medicine</rights><rights>2011 American Society for Reproductive Medicine</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c664t-6d62aa01054d6c183c2282d3fea9ce348b3480148af152779383e52a57fd3f063</citedby><cites>FETCH-LOGICAL-c664t-6d62aa01054d6c183c2282d3fea9ce348b3480148af152779383e52a57fd3f063</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.fertnstert.2010.09.062$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,552,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23916806$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21067727$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:122004088$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Murkes, Daniel, M.D</creatorcontrib><creatorcontrib>Conner, Peter, M.D., Ph.D</creatorcontrib><creatorcontrib>Leifland, Karin, M.D., Ph.D</creatorcontrib><creatorcontrib>Tani, Edneia, M.D., Ph.D</creatorcontrib><creatorcontrib>Beliard, Aude, M.D., Ph.D</creatorcontrib><creatorcontrib>Lundström, Eva, M.D., Ph.D</creatorcontrib><creatorcontrib>Söderqvist, Gunnar, M.D., Ph.D</creatorcontrib><title>Effects of percutaneous estradiol–oral progesterone versus oral conjugated equine estrogens–medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women</title><title>Fertility and sterility</title><addtitle>Fertil Steril</addtitle><description>In a prospective, randomized clinical study 77 women were assigned randomly to receive sequential hormone therapy with either conventional oral conjugated equine estrogens (0.625 mg) with the addition on 14 of the 28 days of oral medroxyprogesterone acetate (5 mg) or natural E2 gel (1.5 mg) with oral micronized P (200 mg) on 14 of the 28 days of each cycle. Because oral conjugated equine estrogens–medroxyprogesterone acetate induced a highly significant increase in breast cell proliferation in contrast to percutaneous E2 –oral P with a difference between therapies approaching significance, the former therapy has a marked impact on the breast whereas natural percutaneous E2 –oral micronized P has not.</description><subject>acetates</subject><subject>Administration, Oral</subject><subject>bcl-2 protein</subject><subject>Biological and medical sciences</subject><subject>Biopsy</subject><subject>breast</subject><subject>Breast - cytology</subject><subject>Breast - drug effects</subject><subject>Breast - metabolism</subject><subject>Breast Neoplasms - epidemiology</subject><subject>Breast Neoplasms - prevention & control</subject><subject>Cell Division - drug effects</subject><subject>cell proliferation</subject><subject>Contraceptive Agents, Female - administration & dosage</subject><subject>Contraceptive Agents, Female - adverse effects</subject><subject>estrogen</subject><subject>Estrogen Replacement Therapy - adverse effects</subject><subject>Estrogen Replacement Therapy - methods</subject><subject>estrogens</subject><subject>Estrogens - administration & dosage</subject><subject>Estrogens - adverse effects</subject><subject>Estrogens, Conjugated (USP) - administration & dosage</subject><subject>Estrogens, Conjugated (USP) - adverse effects</subject><subject>Female</subject><subject>gels</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>hormone replacement therapy</subject><subject>horses</subject><subject>Human health sciences</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Medical sciences</subject><subject>Medicin och hälsovetenskap</subject><subject>medroxyprogesterone</subject><subject>Medroxyprogesterone Acetate - administration & dosage</subject><subject>Medroxyprogesterone Acetate - adverse effects</subject><subject>micronized progesterone</subject><subject>Médecine de la reproduction (Gynécologie, andrologie, obstétrique)</subject><subject>normal breast tissue</subject><subject>Obstetrics and Gynecology</subject><subject>Percutaneous estradiol</subject><subject>progesterone</subject><subject>proliferation</subject><subject>Prospective Studies</subject><subject>Proto-Oncogene Proteins c-bcl-2 - metabolism</subject><subject>randomized clinical trials</subject><subject>Reproductive medicine (gynecology, andrology, obstetrics)</subject><subject>Risk Factors</subject><subject>Sciences de la santé humaine</subject><subject>women</subject><issn>0015-0282</issn><issn>1556-5653</issn><issn>1556-5653</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>D8T</sourceid><recordid>eNqNk81u1DAQxyMEoqXwCuAL4pTFdmLHuSDRqnxIlTiUni3HmWy9zdpbO2nZG-_A4_A2PAmTzbYVSEhI-bDGv79nPP47ywijC0aZfLtadBAHnwb8LjjFMK0XVPJH2SETQuZCiuJxdkgpEznlih9kz1JaUUolq_jT7IAzKquKV4fZz9OuAzskEjqygWjHwXgIYyKQhmhaF_pf33-EaHqyiWEJU8bggdxATAjtJmzwq3FpBmgJXI8OZyctwj6hdg1tDN-2f6iNhQF5EjxpIpg0EAv9LkPvcGNmcDhjfEsa2-d8ig_gPMHnEkw_XG7JbViDf5496Uyf4MX-f5RdfDj9evIpP_vy8fPJ-7PcSlkOuWwlNwabJMpWWqYKy7ElbdGBqS0UpWrwpaxUpmOCV1VdqAIEN6LqEKKyOMryed10C5ux0Zvo1iZudTBO70NXOAItykqpia__yeNe2gfRnZBxTmlJlUJtMWt7B0vQITZO3_CddDce-6U2VjegOZdKM1EIQVH1Zlbh8tcj9lmvXZp6Oh-mVqIoK0brGkk1kzaGlCJ099Uxqidv6ZV-8JaevKVprdFbKH25TzI2eKr3wjszIfB6D5hkTd9F461LD1xRM6l2_Xw1c50J2iwjMhfnmEmgX3lVVgUSxzMBeKw3DqJO1oG30LqIbtVtcP9T77u_FrG98w4ru4ItpFUYo0fbaKYT11SfT7dluiyMUi4r7Opv7mIZHw</recordid><startdate>20110301</startdate><enddate>20110301</enddate><creator>Murkes, Daniel, M.D</creator><creator>Conner, Peter, M.D., Ph.D</creator><creator>Leifland, Karin, M.D., Ph.D</creator><creator>Tani, Edneia, M.D., Ph.D</creator><creator>Beliard, Aude, M.D., Ph.D</creator><creator>Lundström, Eva, M.D., Ph.D</creator><creator>Söderqvist, Gunnar, M.D., Ph.D</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>Q33</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>20110301</creationdate><title>Effects of percutaneous estradiol–oral progesterone versus oral conjugated equine estrogens–medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women</title><author>Murkes, Daniel, M.D ; Conner, Peter, M.D., Ph.D ; Leifland, Karin, M.D., Ph.D ; Tani, Edneia, M.D., Ph.D ; Beliard, Aude, M.D., Ph.D ; Lundström, Eva, M.D., Ph.D ; Söderqvist, Gunnar, M.D., Ph.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c664t-6d62aa01054d6c183c2282d3fea9ce348b3480148af152779383e52a57fd3f063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>acetates</topic><topic>Administration, Oral</topic><topic>bcl-2 protein</topic><topic>Biological and medical sciences</topic><topic>Biopsy</topic><topic>breast</topic><topic>Breast - cytology</topic><topic>Breast - drug effects</topic><topic>Breast - metabolism</topic><topic>Breast Neoplasms - epidemiology</topic><topic>Breast Neoplasms - prevention & control</topic><topic>Cell Division - drug effects</topic><topic>cell proliferation</topic><topic>Contraceptive Agents, Female - administration & dosage</topic><topic>Contraceptive Agents, Female - adverse effects</topic><topic>estrogen</topic><topic>Estrogen Replacement Therapy - adverse effects</topic><topic>Estrogen Replacement Therapy - methods</topic><topic>estrogens</topic><topic>Estrogens - administration & dosage</topic><topic>Estrogens - adverse effects</topic><topic>Estrogens, Conjugated (USP) - administration & dosage</topic><topic>Estrogens, Conjugated (USP) - adverse effects</topic><topic>Female</topic><topic>gels</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>hormone replacement therapy</topic><topic>horses</topic><topic>Human health sciences</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Medical sciences</topic><topic>Medicin och hälsovetenskap</topic><topic>medroxyprogesterone</topic><topic>Medroxyprogesterone Acetate - administration & dosage</topic><topic>Medroxyprogesterone Acetate - adverse effects</topic><topic>micronized progesterone</topic><topic>Médecine de la reproduction (Gynécologie, andrologie, obstétrique)</topic><topic>normal breast tissue</topic><topic>Obstetrics and Gynecology</topic><topic>Percutaneous estradiol</topic><topic>progesterone</topic><topic>proliferation</topic><topic>Prospective Studies</topic><topic>Proto-Oncogene Proteins c-bcl-2 - metabolism</topic><topic>randomized clinical trials</topic><topic>Reproductive medicine (gynecology, andrology, obstetrics)</topic><topic>Risk Factors</topic><topic>Sciences de la santé humaine</topic><topic>women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Murkes, Daniel, M.D</creatorcontrib><creatorcontrib>Conner, Peter, M.D., Ph.D</creatorcontrib><creatorcontrib>Leifland, Karin, M.D., Ph.D</creatorcontrib><creatorcontrib>Tani, Edneia, M.D., Ph.D</creatorcontrib><creatorcontrib>Beliard, Aude, M.D., Ph.D</creatorcontrib><creatorcontrib>Lundström, Eva, M.D., Ph.D</creatorcontrib><creatorcontrib>Söderqvist, Gunnar, M.D., Ph.D</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Université de Liège - Open Repository and Bibliography (ORBI)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>Fertility and sterility</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Murkes, Daniel, M.D</au><au>Conner, Peter, M.D., Ph.D</au><au>Leifland, Karin, M.D., Ph.D</au><au>Tani, Edneia, M.D., Ph.D</au><au>Beliard, Aude, M.D., Ph.D</au><au>Lundström, Eva, M.D., Ph.D</au><au>Söderqvist, Gunnar, M.D., Ph.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of percutaneous estradiol–oral progesterone versus oral conjugated equine estrogens–medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women</atitle><jtitle>Fertility and sterility</jtitle><addtitle>Fertil Steril</addtitle><date>2011-03-01</date><risdate>2011</risdate><volume>95</volume><issue>3</issue><spage>1188</spage><epage>1191</epage><pages>1188-1191</pages><issn>0015-0282</issn><issn>1556-5653</issn><eissn>1556-5653</eissn><coden>FESTAS</coden><abstract>In a prospective, randomized clinical study 77 women were assigned randomly to receive sequential hormone therapy with either conventional oral conjugated equine estrogens (0.625 mg) with the addition on 14 of the 28 days of oral medroxyprogesterone acetate (5 mg) or natural E2 gel (1.5 mg) with oral micronized P (200 mg) on 14 of the 28 days of each cycle. Because oral conjugated equine estrogens–medroxyprogesterone acetate induced a highly significant increase in breast cell proliferation in contrast to percutaneous E2 –oral P with a difference between therapies approaching significance, the former therapy has a marked impact on the breast whereas natural percutaneous E2 –oral micronized P has not.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>21067727</pmid><doi>10.1016/j.fertnstert.2010.09.062</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0015-0282 |
| ispartof | Fertility and sterility, 2011-03, Vol.95 (3), p.1188-1191 |
| issn | 0015-0282 1556-5653 1556-5653 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_547886 |
| source | MEDLINE; SWEPUB Freely available online; Access via ScienceDirect (Elsevier); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | acetates Administration, Oral bcl-2 protein Biological and medical sciences Biopsy breast Breast - cytology Breast - drug effects Breast - metabolism Breast Neoplasms - epidemiology Breast Neoplasms - prevention & control Cell Division - drug effects cell proliferation Contraceptive Agents, Female - administration & dosage Contraceptive Agents, Female - adverse effects estrogen Estrogen Replacement Therapy - adverse effects Estrogen Replacement Therapy - methods estrogens Estrogens - administration & dosage Estrogens - adverse effects Estrogens, Conjugated (USP) - administration & dosage Estrogens, Conjugated (USP) - adverse effects Female gels Gynecology. Andrology. Obstetrics hormone replacement therapy horses Human health sciences Humans Internal Medicine Medical sciences Medicin och hälsovetenskap medroxyprogesterone Medroxyprogesterone Acetate - administration & dosage Medroxyprogesterone Acetate - adverse effects micronized progesterone Médecine de la reproduction (Gynécologie, andrologie, obstétrique) normal breast tissue Obstetrics and Gynecology Percutaneous estradiol progesterone proliferation Prospective Studies Proto-Oncogene Proteins c-bcl-2 - metabolism randomized clinical trials Reproductive medicine (gynecology, andrology, obstetrics) Risk Factors Sciences de la santé humaine women |
| title | Effects of percutaneous estradiol–oral progesterone versus oral conjugated equine estrogens–medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T08%3A05%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20percutaneous%20estradiol%E2%80%93oral%20progesterone%20versus%20oral%20conjugated%20equine%20estrogens%E2%80%93medroxyprogesterone%20acetate%20on%20breast%20cell%20proliferation%20and%20bcl-2%20protein%20in%20healthy%20women&rft.jtitle=Fertility%20and%20sterility&rft.au=Murkes,%20Daniel,%20M.D&rft.date=2011-03-01&rft.volume=95&rft.issue=3&rft.spage=1188&rft.epage=1191&rft.pages=1188-1191&rft.issn=0015-0282&rft.eissn=1556-5653&rft.coden=FESTAS&rft_id=info:doi/10.1016/j.fertnstert.2010.09.062&rft_dat=%3Cproquest_swepu%3E853471099%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=853471099&rft_id=info:pmid/21067727&rft_els_id=S0015028210026750&rfr_iscdi=true |